Clinical Trials on Immune-related Adverse Event in Japan

Total 115 results

Eisai Co., Ltd.

Active, not recruiting

A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

Parkinson Disease

Japan
Andreas Benesic, MD
MetaHeps GmbH

Unknown

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Adverse Reaction to Drug | Drug-induced Disorder of Liver

Hong Kong, Australia, Germany, Japan, Korea, Republic of
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

Japan
Osaka City University

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Non-Hodgkin's Lymphoma

Japan
Mayo Clinic
Nagoya University

Completed

Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis

IgG4-related Disease | IgG4-related Sclerosing Cholangitis

United States, Japan
Sanofi

Completed

Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Eli Lilly and Company

Completed

A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Safety of Insulin Detemir in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey of Production of Insulin Aspart Specific Antibody

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Paediatric Subjects - Special Survey

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Paediatric Subjects

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Patients With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Type 1 or Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Sanofi

Completed

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Nihon Pharmaceutical Co., Ltd

Recruiting

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Autoimmune Encephalitis

Japan
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
AstraZeneca

Completed

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Kurume University

Completed

Cardiac Sarcoidosis and FDG-PET

Dilated Cardiomyopathy | Sarcoidosis

Japan
Takeda

Completed

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Relapsed/Refractory Multiple Myeloma

Japan
Takeda

Completed

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Relapsed and/or Refractory Multiple Myeloma

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Japan
Takeda

Completed

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

Japan
Jichi Medical University
Takara Bio Inc.

Unknown

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Japan
Kosei Hasegawa, MD, PhD

Recruiting

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Carcinoma, Ovarian Epithelial

Japan
Astellas Pharma Inc

Completed

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Celgene

Recruiting

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Lymphoma

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Eli Lilly and Company
Alkermes, Inc.

Completed

A Study for Patients With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan, Taiwan
Eisai Inc.

Completed

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Lymphoma, T-cell, Peripheral | Lymphoma, T-cell, Cutaneous

Japan
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1)

Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

Type 1 Diabetes Mellitus

Japan
Boehringer Ingelheim

Terminated

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Ovarian Neoplasms

Japan
Eisai Co., Ltd.

Completed

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Japan
Pfizer

Active, not recruiting

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Japan
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Ottawa Heart Institute Research Corporation
Canadian Institutes of Health Research (CIHR); Ontario Ministry of Health and...

Recruiting

Cardiac Sarcoidosis Multi-Center Prospective Cohort (CHASM-CS)

Cardiac Sarcoidosis

Canada, Japan
Amgen

Active, not recruiting

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

IgG4 Related Disease

Poland, Spain, United States, Argentina, Australia, Canada, China, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Sweden, Turkey, United Kingdom
Astellas Pharma Inc

Completed

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Zenas BioPharma (USA), LLC

Recruiting

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease (INDIGO)

IgG4 Related Disease

United States, Korea, Republic of, Spain, China, Japan, France, Mexico, Poland, Taiwan, Hungary, Italy, United Kingdom, Argentina, Netherlands, Turkey, Hong Kong, Sweden, Germany, Canada

Clinical Trials on Immune-related Adverse Event in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations